Zhu Q, Gao BQ, Zhang JF, Shi LP, Zhang GQ. Successful treatment of lichen amyloidosis coexisting with atopic dermatitis by dupilumab: Four case reports. World J Clin Cases 2023; 11(11): 2549-2558 [PMID: 37123319 DOI: 10.12998/wjcc.v11.i11.2549]
Corresponding Author of This Article
Guo-Qiang Zhang, MD, Director, Professor, Department of Dermatology, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Shijiazhuang 050031, Hebei Province, China. zlx090702@163.com
Research Domain of This Article
Dermatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Qing Zhu, Jin-Fang Zhang, Li-Ping Shi, Guo-Qiang Zhang, Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang 050031, Hebei Province, China
Bing-Quan Gao, Department of Burns and Plastic Surgery, The First Hospital of Hebei Medical University, Shijiazhuang 050031, Hebei Province, China
Author contributions: Gao BQ and Zhang JF performed the pathological studies, laboratory testing, and clinical data collection; Zhu Q and Shi LP were responsible for patient care and drafted this manuscript; Zhang GQ revised the manuscript critically for important intellectual content; all authors contributed to the article and approved the submitted version.
Informed consent statement: Written Informed consent was obtained from all patients for the publication of this case report.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works0 on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Guo-Qiang Zhang, MD, Director, Professor, Department of Dermatology, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Shijiazhuang 050031, Hebei Province, China. zlx090702@163.com
Received: December 27, 2022 Peer-review started: December 27, 2022 First decision: January 20, 2023 Revised: February 2, 2023 Accepted: March 22, 2023 Article in press: March 22, 2023 Published online: April 16, 2023 Processing time: 100 Days and 6.9 Hours
Abstract
BACKGROUND
Lichen amyloidosis (LA) is a chronic, severely pruritic skin disease, which is the most common form of primary cutaneous amyloidosis. The treatment of LA has been considered to be difficult. LA may be associated with atopic dermatitis (AD), and in this setting, the treatment options may be more limited. Herein, we report four cases of LA associated with AD successfully treated by dupilumab.
CASE SUMMARY
In this article, we describe four cases of patients who presented with recurrent skin rash accompanied by severe generalized intractable pruritus, diagnosed with refractory LA coexisting with chronic AD. Previous treatments had not produced any apparent improvement. Thus, we administered dupilumab injection subcutaneously at a dose of 600 mg for the first time and 300 mg every 2 wk thereafter. Their lesions all markedly improved.
CONCLUSION
Dupilumab may be a new useful treatment for LA coexisting with AD.
Core Tip: Lichen amyloidosis (LA) is a chronic, severely pruritic skin disease, which is the most common subtype of primary cutaneous amyloidosis characterized by deposition of amyloid protein on the skin without visceral involvement. The treatment of LA has been considered difficult, with high relapse rates. In this article, we present four cases of LA associated with atopic dermatitis (AD) treated with dupilumab who achieved remarkable results. Our observations suggested that dupilumab may shed light on the systematic treatment of refractory LA patients with AD.
